Low colonic absorption drugs: risks and opportunities in the development of oral extended release products

References

• Lipp R. Major advances in oral drug delivery over the past 15 years. Am Pharm Rev October. 2013;31. [cited 2017 Oct 11]. Available from: http://www.americanpharmaceuticalreview.com/Featured-Articles/148747-Major-Advances-in-Oral-Drug-Delivery-over-the-Past-15-Years/
   Google Scholar
• Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut. 1986 August;27(8):886–892.
   PubMed Web of Science ®Google Scholar
• Washington N, Washington CG, Wilson C. Chapter 7. Drug delivery to the large intestine and rectum. In: Washington N, Washington CG, Wilson C, eds. Physiological pharmaceutics barriers to drug absorption. 2nd ed. New york, NY:Taylor and Francis. 2001.
   Google Scholar
• Connor A, King G, Jones K Evaluation of human regional bioavailability to assess whether modified release development is feasible, http://mms.technologynetworks.net/posters/510.pdf. Accessed August 30, 2014.
   Google Scholar
• Tannergren C, Bergendal A, Lennernas H, et al. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Mol Pharmaceutics. 2009;6(1):60–73.
   PubMed Web of Science ®Google Scholar
• Washington N, Washington CG, Wilson C. Chapter 5. The stomach. In: Washington N, Washington CG, Wilson C, eds. Physiological pharmaceutics barriers to drug absorption. 2nd ed. London:Taylor and Francis. 2001.
   Google Scholar
• Sjogren E, Abrahamsson B, Augustijns P, et al. In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. Eur J Pharm Sci. 2014 Jun;16(57):99–151.
   Google Scholar
• Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing. Mol Pharm. 2010 Oct 4; 7(5):1388–1405.
   PubMed Web of Science ®Google Scholar
• Hu M, Li X. Oral bioavailability: basic principles, advanced concepts, and applications. 1 ed. MA,Wiley; 2011.
   Google Scholar
• Zhang QY, Dunbar D, Ostrowska A, et al. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos. 1999 Jul;27(7):804–809.
   PubMed Web of Science ®Google Scholar
• Thorn M, Finnstrom N, Lundgren S, et al. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol. 2005 Jul;60(1):54–60.
   PubMed Web of Science ®Google Scholar
• Berggren S, Gall C, Wollnitz N, et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm. 2007 Mar-Apr;4(2):252–257.
   PubMedGoogle Scholar
• Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev. 1999 Jun;51(2):135–158.
   PubMed Web of Science ®Google Scholar
• Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol. 2009 May;61(5):541–558.
   PubMed Web of Science ®Google Scholar
• Soergel KH. Showdown at the tight junction. Gastroenterology. 1993 Oct;105(4):1247–1250.
   PubMed Web of Science ®Google Scholar
• Norris DA, Puri N, Sinko PJ. The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliv Rev. 1998 Dec 1;34(2–3):135–154.
   PubMed Web of Science ®Google Scholar
• Madara JL, Pappenheimer JR. Structural basis for physiological regulation of paracellular pathways in intestinal epithelia. J Membr Biol. 1987;100(2):149–164.
   PubMed Web of Science ®Google Scholar
• Lennernas H. Human intestinal permeability. J Pharm Sci. 1998 Apr;87(4):403–410.
   PubMed Web of Science ®Google Scholar
• Proctor WR, Bourdet DL, Thakker DR. Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos. 2008 Aug;36(8):1650–1658.
   PubMed Web of Science ®Google Scholar
• Vidon N, Chaussade S, Noel M, et al. Metformin in the digestive tract. Diabetes Res Clin Pract. 1988 Feb 19;4(3):223–229.
   PubMed Web of Science ®Google Scholar
• Washington N, Washington CG, Wilson C. Chapter 1. Cell membranes, epithelial barriers and drug absorption. In: Washington N, Washington CG, Wilson C, eds. Physiological pharmaceutics barriers to drug absorption. 2nd ed. New york, NY:Taylor and Francis. 2001.
   Google Scholar
• Sherwood L, Appendix C. Storage, replication, and expression of genetic information. Sherwood L, ed. Fundamentals of Human Physiology. Belomont, CA. 2011.
   Google Scholar
• Hardy JG, Evans DF, Zaki I, et al. Evaluation of an enteric coated naproxen tablet using gamma scintigraphy and pH monitoring. Int J Pharm. 1987;37(3):245–250.
   Web of Science ®Google Scholar
• Tsume Y, Amidon GL, Takeuchi S. Dissolution effect of gastric and intestinal pH for a BCS class II drug, pioglitazone: new in vitro dissolution system to predict in vivo dissolution. J Bioequiv Availab. 2013;5(6):224–227.
   Google Scholar
• Castan C, Crowley PJ, Guimberteau F, et al., inventors; WO 2005051322 A2. Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods. 2005.
   Google Scholar
• Oh CK, inventor Novel formulations of Carvedilol, WO2003028718 2003.
   Google Scholar
• Stenberg P, Luthman K, Artursson P. Virtual screening of intestinal drug permeability. J Cont Release. 2000 Mar 1;65(1–2):231–243.
   PubMed Web of Science ®Google Scholar
• El-Kattan A, Varma M. Chapter 1. Oral absorption, intestinal metabolism and human oral bioavailability. In: Paxton J, ed. Topics on drug metabolism. Croatia. 2012.
   Google Scholar
• Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. 2002 Jun;42(6):620–643.
   PubMed Web of Science ®Google Scholar
• Petri N, Lennernas H. Chapter 9. In vivo permeability studies in the gastrointestinal tract of humans. In: Waterbeemd H, Testa B, eds. Drug bioavailability: estimation of solubility. Permeability, Absorption and Bioavailability; WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 2009.
   Google Scholar
• Lai Y. Chapter 8. Drug transporters in drug discovery and development. In: Lai Y, ed. Transporters in drug discovery and development: detailed concepts and best practice. Cambridge, UK:Woodhead Publishing Limited; 2013.
   Google Scholar
• Intestinal Epithelia, http://dbts.ucsf.edu/fdatransportal/organs/small-intestine/. Access December 28, 2014.
   Google Scholar
• Russel FGM. Chapter 2. Transporters: importance in drug absorption, distribution, and removal. In: Pang KS, Rodrigues AD, Peter RM, eds. Enzyme- and transporter-based drug-drug interactions. Springer New York Dordrecht Heidelberg London; 2010.
   Google Scholar
• Koepsell H. Chapter 2. Organic cation and zwitterion transporters (OCTs, OCTNs). In: You G, Morris ME, eds. Drug transporters: molecular characterization and role in drug disposition. MA:John Wiley & Sons, Inc.; 2014.
   Google Scholar
• Knutter I, Wollesky C, Kottra G, et al. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432–441.
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang S, Hu M. Chapter 11 - oral absorption basics: pathways, physico-chemical and biological factors affecting absorption. In: Porter YQCGZZLR, ed. Developing solid oral dosage forms. San Diego: Academic Press; 2009. p. 263–288.
   Google Scholar
• Hu M, Amidon GL. Passive and carrier-mediated intestinal absorption components of captopril. J Pharm Sci. 1988 Dec;77(12):1007–1011.
   PubMed Web of Science ®Google Scholar
• Arakawa H, Shirasaka Y, Haga M, et al. Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5. Biopharm Drug Dispos. 2012 Sep;33(6):332–341.
   PubMed Web of Science ®Google Scholar
• Park MS, Okochi H, Benet LZ. Is ciprofloxacin a substrate of P-glycoprotein? Arch Drug Inf. 2011 Mar;4(1):1–9.
   PubMedGoogle Scholar
• Merino G, Alvarez AI, Pulido MM, et al. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006 Apr;34(4):690–695.
   PubMed Web of Science ®Google Scholar
• Ziegler TR, Fernandez-Estivariz C, Gu LH, et al. Distribution of the H+/peptide transporter PepT1 in human intestine: up-regulated expression in the colonic mucosa of patients with short-bowel syndrome. Am J Clin Nutr. 2002 May;75(5):922–930.
   PubMed Web of Science ®Google Scholar
• Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 2005 Dec;20(6):452–477.
   PubMedGoogle Scholar
• Barr WH, Zola EM, Candler EL, et al. Differential absorption of amoxicillin from the human small and large intestine. Clin Pharmacol Ther. 1994 Sep;56(3):279–285.
   PubMed Web of Science ®Google Scholar
• Li M, Anderson GD, Phillips BR, et al. Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547–555.
   PubMed Web of Science ®Google Scholar
• Lennernas H, Nilsson D, Aquilonius S-M, et al. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br J Clin Pharmacol. 1993;(35):243–250.
   Google Scholar
• Camargo SM, Vuille-dit-Bille RN, Mariotta L, et al. The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson’s disease. J Pharmacol Exp Ther. 2014 Oct;351(1):114–123.
   PubMed Web of Science ®Google Scholar
• Lai Y. 2. drug transporters in drug discovery and development. drug transporters in drug discovery and development: Lai Y, ed. Transporters in drug discovery and development: Detailed concepts and best practice: Woodhead Publishing Limited 2013. doi:10.1533/9781908818287.633
   Google Scholar
• Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res. 2003 Oct;20(10):1595–1599.
   PubMed Web of Science ®Google Scholar
• Dahan A, Amidon GL. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371–7.
   PubMed Web of Science ®Google Scholar
• Makhey VD, Guo A, Norris DA, et al. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res. 1998 Aug;15(8):1160–1167.
   PubMed Web of Science ®Google Scholar
• Arza RA, Gonugunta CS, Veerareddy PR. Formulation and evaluation of swellable and floating gastroretentive ciprofloxacin hydrochloride tablets. AAPS PharmSciTech. 2009;10(1):220–226.
   PubMed Web of Science ®Google Scholar
• Shanthi CN, Mahato AK, Gupta R. A review on Captopril oral sustained/controlled release formulations. Int J Drug Dev Res. 2010;2(2):40–46.
   Google Scholar
• Colon and delivery, http://shodhganga.inflibnet.ac.in/bitstream/10603/8027/8/08_chapter%202.pdf. Accessed September 1, 2014.
   Google Scholar
• Patel GN, Patel GC, Patel RB, et al. Oral colon-specific drug delivery: an overview. Drug Deliv Technol. 2006;6(7):62–72.
   Google Scholar
• Sousa T, Paterson R, Moore V, et al. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm. 2008 Nov 3;363(1–2): 1–25.
   PubMed Web of Science ®Google Scholar
• Basit AW, Lacey LF. Colonic metabolism of ranitidine: implications for its delivery and absorption. Int J Pharm. 2001;227(1–2): 157–165. 10/4/.
   PubMedGoogle Scholar
• Parrott N, Lave T. Applications of physiologically based absorption models in drug discovery and development. Mol Pharm. 2008 Sep-Oct;5(5):760–775.
   PubMed Web of Science ®Google Scholar
• Menon R, Cefali E, Wilding I, et al. The assessment of human regional drug absorption of free acid and sodium salt forms of acipimox, in healthy volunteers, to direct modified release formulation strategy. Biopharm Drug Dispos. 2009 Dec;30(9):508–516.
   PubMed Web of Science ®Google Scholar
• Liu HY, Pi XT, Zheng XL, et al. Pharmacokinetics of aminophylline delivered to the small intestine and colon using remote controlled capsules. Chin Med J. 2010 Feb 5;123(3):320–325.
   PubMed Web of Science ®Google Scholar
• Cundy KC, Sastry S, Luo W, et al. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol. 2008 Dec;48(12):1378–1388.
   PubMed Web of Science ®Google Scholar
• Wong PSL, Yan D, Hwang S, et al. EP 1677756 A2, Administration of levodopa and carbidopa. 2004.
   Google Scholar
• Drewe J, Beglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol. 1992;33(1):39–43.
   PubMed Web of Science ®Google Scholar
• Gande S, Rao Y. Sustained-release effervescent floating matrix tablets of baclofen: development, optimization and in vitro-in vivo evaluation in healthy human volunteers. Daru. 2011;19(3):202–209.
   PubMed Web of Science ®Google Scholar
• Sugihara H, Matsui Y, Takeuchi H, et al. Development of a gastric retentive system as a sustained-release formulation of pranlukast hydrate and its subsequent in vivo verification in human studies. Eur J Pharm Sci. 2014;53:62–68.
   PubMed Web of Science ®Google Scholar
• Terao T, Matsuda K, Shouji H. Improvement in site-specific intestinal absorption of furosemide by Eudragit L100–55. J Pharm Pharmacol. 2001 Apr;53(4):433–440.
   PubMed Web of Science ®Google Scholar
• Connor A, Evans P, Doto J, et al. An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat. J Clin Pharmacol. 2009 May;49(5):606–612.
   PubMed Web of Science ®Google Scholar
• FDA clinical pharmacology and biopharmaceutics reviews - Gralise (gabapentin) Tablets 300 mg and 600 mg http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022544Orig1s000ClinPharmR.pdf. Accessed on September 10, 2010.
   Google Scholar
• Uchino H, Kanai Y, Kim DK, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002 Apr;61(4):729–737.
   PubMed Web of Science ®Google Scholar
• Dickens D, Webb SD, Antonyuk S, et al. Transport of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol. 2013 Jun 1;85(11):1672–1683.
   PubMed Web of Science ®Google Scholar
• Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993 Feb;10(2):276–281.
   PubMed Web of Science ®Google Scholar
• Lal R, Sukbuntherng J, Luo W, et al. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010;69(5):498–507.
   PubMed Web of Science ®Google Scholar
• Eaimtrakarn S, Itoh Y, Kishimoto JI, et al. Retention and transit of intestinal mucoadhesive films in rat small intestine. Int J Pharm. 2001 Aug 14;224(1–2):61–67.
   PubMed Web of Science ®Google Scholar
• Varum FJ, McConnell EL, Sousa JJ, et al. Mucoadhesion and the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst. 2008;25(3):207–258.
   PubMed Web of Science ®Google Scholar
• Guimberteau F, Dargelas F, inventors; US 20070264346, Multimicroparticulate pharmaceutical forms for oral administration. 2007
   Google Scholar
• Micropump - Flamel, http://www.flamel.com/drug-delivery-platforms/micropump/. Accessed September 28, 2014.
   Google Scholar
• Nolte K, Backfisch G, Neidlein R. In vitro absorption studies with carvedilol using a new model with porcine intestine called BM-RIMO (Boehringer-Mannheim ring model). Arzneimittel-Forschung. 1999 Sep;49(9):745–749.
   PubMed Web of Science ®Google Scholar
• Depomed technology, http://www.depomed.com/technology. Accessed September 10, 2014.
   Google Scholar
• Shell JW, Louie-Helm J, Markey M US 6340475, Extending the duration of drug release within the stomach during the fed mode 1997.
   Google Scholar
• Shell JW, Louie-Helm J, Markey M, inventors; US 6635280, Efficiency absorption in stomach; FDA Orange book listed patent for gabapentin. 1997.
   Google Scholar
• Gusler G, Berner B, Chau M, et al., inventors; US 6723340, Optimal polymer mixtures for gastric retentive tablets 2001.
   Google Scholar
• Dharmadhikari NB, Zala YR WO 2005101983, Gastric retention system. 2004.
   Google Scholar
• Gastro retentive system - Sunpharma, http://www.sunpharma.in/gastro-retentive.htm. Accessed September 30, 2014.
   Google Scholar
• clinicaltrials.gov. A clinical evaluation of the safety of Baclofen GRS ER capsules, http://clinicaltrials.gov/show/NCT01797185. Accessed January 3, 2015.
   Google Scholar
• Omidian H, Fesharaki S, Park K. Chapter 6. Oral controlled delivery mechanisms and technologies. In: Wilson CG, ed. Controlled release in oral drug delivery. New york,USA. 2011.
   Google Scholar
• Singh LPKSR, Umalkar DG, Chauhan VK, et al. Floating effervescent tablet: a review. J Pharm Biomed Sci. 2011;5(11):1–6.
   Google Scholar
• Srikanth MV, Ram BJ, Sunil SA, et al. Gastroretentive drug delivery systems novel approaches its eveluation review Int J Pharm Sci Rev Res. 2011;10(1):203–216.
   Google Scholar
• Ranade VV, Cannon JB. Chapter 5. Oral drug delivery. In: Ranade VV, Cannon JB, eds. Drug delivery systems. Third ed. Boca Raton, Florida:CRC Press. 2011.
   Google Scholar
• Rajak P, Bhattacharya A, Sharma N, et al. Gastro-retentive floating drug delivery system - an approach in gastroretentive drug delivery. Int J Pharm Pharm Sci. 2011;3(suppl 4):9–16.
   Google Scholar
• Gabor F, Fillafer C, Neutsch L, et al. Chapter 12. Improving oral delivery. In: Scha¨fer-Korting M, ed. Drug delivery. Springer-Verlag Berlin Heidelberg; 2010.
   Google Scholar
• Sheth PR, Tossounian J. The hydrodynamically balanced system (HBSTM): a novel drug delivery system for oral use. Drug Dev Ind Pharm. 1984;10(2):313–339.
   Web of Science ®Google Scholar
• Amit JK, Rammulrajsinh R, Sonali D, et al. Hydrodynamically balanced systems (HBS): innovative approach of gastroretention: a review. Int J PharmTech Res. 2011;3(3):1495–1508.
   Google Scholar
• Notari. Chapter 5. V. Drug delivery to prolong duration. In: Notari, ed. Biopharmaceutics and clinical pharmacokinetics: an introduction. New york. Fourth. 1986.
   Google Scholar
• Friedman M, Klausner E, Lavy E, et al. US 6685962, Enclosed in insoluble membranes 1999.
   Google Scholar
• Abramov E, Carni G, Kirmayer D, et al., inventors; WO 2012059815, Accordion pill comprising levodopa for an improved treatment of Parkinson’s disease symptoms. 2010.
   Google Scholar
• Klausner EA, Lavy E, Stepensky D, et al. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm Res. 2002 Oct;19(10):1516–1523.
   PubMed Web of Science ®Google Scholar
• Intecpipeline-Accordion Pill, http://intecpharma.com/pipleline/. Accessed September 23, 2014.
   Google Scholar
• The Accordion Pill™ - World Drug Delivery & Formulation 2014. http://cdnddfeventcom/pdf/LimorDaggan_2014pdf Accessed on September 23, 2014.
   Google Scholar
• Besse J. EP 00956599 B1, Floating pharmaceutical composition comprising an active phase and a non-active phase 1999.
   Google Scholar
• Jerome B, inventor WO 2001010417, Floating pharmaceutical composition comprising an active phase and a non-active phase. 1999.
   Google Scholar
• Besse J US 7682629, tablet comprising hydroxymethylcellulose and gas-generating system 1999.
   Google Scholar
• Galenix -Minextab Floating, http://www.galenix.fr/drug-delivery-solutions/minextab-floating.html. Accessed September 16, 2014.
   Google Scholar
• Salix pipeline, http://www.salix.com/about-us/pharmaceutical-research-development/drug-pipeline.aspx. Accessed September 16, 2014.
   Google Scholar
• Chih-Ming C, inventor WO 9640080, Controlled release formulation having a preformed passageway. 1995.
   Google Scholar
• Malaterre V, Ogorka J, Loggia N, et al. Oral osmotically driven systems: 30 years of development and clinical use. Eur J Pharm Biopharm. 2009 Nov;73(3):311–323.
   PubMed Web of Science ®Google Scholar
• Tiwari SB, DiNunzio J, Rajabi-Siahboomi A. Chapter 7. Drug–polymer matrices for extended release. In: Wilson CG, ed. Controlled release in oral drug delivery. 2011.
   Google Scholar
• Skalsky B, Stegemann S. Chapter 13. Coated multiparticulates for controlling drug release. In: Wilson CG, ed. Controlled release in oral drug delivery. 2011.
   Google Scholar
• Gastro-retentive drug delivery technology - Skyepharma, http://www.skyepharma.com/Technologies/Oral_drug_delivery_technologies/Gastro_retentive_technology/Default.aspx?id=78. Accessed September 29, 2014.
   Google Scholar
• Skyepharma.com. Madopar DR, http://www.skyepharma.com/Products/Oral_products/Approved_oral_products/Madopar_DR/Default.aspx?id=149. Accessed January 5, 2015.
   Google Scholar
• Gao P, Nie X, Zou M, et al. Recent advances in materials for extended-release antibiotic delivery system. J Antibiot (Tokyo). 2011 Sep;64(9):625–634.
   PubMed Web of Science ®Google Scholar
• COREG CR - FDA label, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed September 25, 2014.
   Google Scholar
• Sampat NG, Kulkarni RV, Sase N, et al. Once daily baclofen sustained release or gastro-retentive system are acceptable alternatives to thrice daily baclofen immediate release at same daily dosage in patients. Neurol India. 2009;57(3):295–299.
   PubMed Web of Science ®Google Scholar
• Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems. Crit Rev Ther Drug Carrier Syst. 2001;18(5):433–458.
   PubMed Web of Science ®Google Scholar
• Drugs@FDA. Moxatag. http://wwwaccessdatafdagov/scripts/cder/drugsatfda/indexcfm?fuseaction=SearchLabel_ApprovalHistory#labelinfo Access January 3, 2015.
   Google Scholar
• How Pulsys Products Work. http://media.corporate-ir.net/media_files/irol/14/147309/pdf/pulsysproducts.pdf. Accessed November 6, 2014.
   Google Scholar
• MiddleBrook Pharmaceuticals corporate fact sheet 2009. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=10&cad=rja&uact=8&ved=0CFkQFjAJ&url=http%3A%2F%2Fphx.corporate-ir.net%2FExternal.File%3Fitem%3DUGFyZW50SUQ9MzQ4NTc3fENoaWxkSUQ9MzM3NDk0fFR5cGU9MQ%3D%3D%26t%3D1&ei=JslGVLLHGfHLsATVtoD4CQ&usg=AFQjCNGUhjG5KrjP0SK0tYC-bQDu93fsKQ&sig2=hhpZs9sH4_1g3MDWp5YPcQ. Accessed October 21, 2014.
   Google Scholar
• Yewale C, Patil S, Kolate A, et al. Oral absorption promoters: opportunities, issues, and challenges. Crit Rev Ther Drug Carrier Syst. 2015;32(5):363–387.
   PubMed Web of Science ®Google Scholar
• Aungst BJ. Absorption enhancers: applications and advances. Aaps J. 2012 Mar;14(1):10–18.
   PubMed Web of Science ®Google Scholar
• Neoral FDA label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50715s10s14lbl.pdf. Accessed August 13, 2017.
   Google Scholar
• Aguirre TA, Teijeiro-Osorio D, Rosa M, et al. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv Drug Deliv Rev. 2016 Nov 15;106(Pt B):223–241.
   PubMed Web of Science ®Google Scholar
• McCartney F, Gleeson JP, Brayden DJ. Safety concerns over the use of intestinal permeation enhancers: a mini-review. Tissue Barriers. 2016;Apr-Jun;4(2:e1176822.
   Web of Science ®Google Scholar
• Moroz E, Matoori S, Leroux JC. Oral delivery of macromolecular drugs: where we are after almost 100years of attempts. Adv Drug Deliv Rev. 2016 Jun 01;101:108–121.
   PubMed Web of Science ®Google Scholar
• Coffin MD, Burke MD. Chapter 17. Controlling release by gastroretention. In: Wilson CG, ed. Controlled release in oral drug delivery. New york, USA. 2011.
   Google Scholar
• Wen H, Park K. Chapter 1. Introduction and overview of oral controlled release formulation design. In: Wen H, Park K, eds. Oral controlled release formulation design and drug delivery. Danvers, MA. 2010.
   Google Scholar
• Zur M, Cohen N, Agbaria R, et al. The biopharmaceutics of successful controlled release drug product: segmental-dependent permeability of glipizide vs metoprolol throughout the intestinal tract. Int J Pharm. 2015 Jul 15;489(1–2):304–310.
   PubMed Web of Science ®Google Scholar
• Prior DV, Connor AL, Wilding IR. Chapter 24. The enterion capsule. In: Rathbone MJ, Hadgraft J, Roberts MS, eds.. Modified-release drug delivery technology. Marcel Dekker, Inc.; New york, USA. 2002.
   Google Scholar
• Shimizu J, Wanke C. IntelliCap: an intelligent, electronic capsule for oral drug delivery & development. Drug Dev Deliv. 2013;13(3). [cited 2017 Oct 11]. Available from: http://drug-dev.com/Main/Back-Issues/ADVANCED-DELIVERY-DEVICES-IntelliCap-An-Intelligen-557.aspx.
   Google Scholar
• Fairstein M, Swissa R, Dahan A. Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine. Aaps J. 2013 Apr;15(2):589–597.
   PubMed Web of Science ®Google Scholar
• Dahan A, Miller JM, Hilfinger JM, et al. High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol Pharm. 2010 Oct 04;7(5):1827–1834.
   PubMed Web of Science ®Google Scholar
• Zur M, Hanson AS, Dahan A. The complexity of intestinal permeability: assigning the correct BCS classification through careful data interpretation. Eur J Pharm Sci. 2014 Sep;30(61):11–17.
   Google Scholar
• Zur M, Gasparini M, Wolk O, et al. The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol. Mol Pharm. 2014 May 05;11(5):1707–1714.
   PubMed Web of Science ®Google Scholar
• Lozoya-Agullo I, Zur M, Beig A, et al. Segmental-dependent permeability throughout the small intestine following oral drug administration: single-pass vs. Doluisio approach to in-situ rat perfusion. Int J Pharm. 2016 Dec 30;515(1–2):201–208.
   PubMedGoogle Scholar
• Klausner EA, Lavy E, Barta M, et al. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm Res. 2003 Sep;20(9):1466–1473.
   PubMed Web of Science ®Google Scholar
• Kagan L, Hoffman A. Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model. Eur J Pharm Biopharm. 2008 May;69(1):238–246.
   PubMed Web of Science ®Google Scholar
• Klausner EA, Eyal S, Lavy E, et al. Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs. J Cont Release. 2003 Feb 14;88(1):117–126.
   PubMed Web of Science ®Google Scholar
• Davis SS, Illum L, Hinchcliffe M. Gastrointestinal transit of dosage forms in the pig. J Pharm Pharmacol. 2001 Jan;53(1):33–39.
   PubMed Web of Science ®Google Scholar
• Razavi M, Karimian H, Yeong CH, et al. Gamma scintigraphic study of the hydrodynamically balanced matrix tablets of Metformin HCl in rabbits. Drug Des Devel Ther. 2015;9:3125–3139.
   PubMed Web of Science ®Google Scholar